Because the development of breakthrough products requires a broad array of expertise and resources across the healthcare spectrum, the formation of strategic partnerships is an important component of Liquidia’s short and
To accelerate Liquidia Engineered Drug Therapies™ into the clinic and ultimately into the marketplace, Liquidia has partnered with pharmaceutical industry leaders to combine their research and development capabilities with Liquidia’s novel particle design and delivery technology.
Similarly, Liquidia has established partnerships with other industry leaders for the development and mcommercialization of non-therapeutic healthcare products, such as gene sequencing, diagnostics, and consumer products.
To further understand the role of particle size, shape, and composition on biodistribution and bioavailability, Liquidia has also partnered with researchers at a variety of academic institutions to explore these fundamental research questions. Liquidia’s collaboration with the University of North Carolina – Chapel Hill is particularly innovative and important to the development of the PRINT technology. Click here to learn more about the Liquidia-UNC partnership.
Liquidia Announces Product Development Collaboration with GlaxoSmithKline
Liquidia and P&G announce collaboration to explore new applications of PRINT®
Liquidia Technologies Announces Collaboration with PATH to Develop Next Generation Pneumococcal VaccineTo learn more about partnership opportunities, please contact firstname.lastname@example.org.